The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.
 
Patrick Y. Wen
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; Blue Earth Diagnostics; deciphera; Deciphera; ElevateBio; Immunomic Therapeutics; Imvax; Integral Health; Karyopharm Therapeutics; KIYATEC; Puma Biotechnology; QED Therapeutics; Taiho Pharmaceutical; Taiho Pharmaceutical; Tocagen; Vascular Biogenics; VBI Vaccines; Voyager Therapeutics
Speakers' Bureau - Merck; Prime Oncology
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Celgene (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Oncoceutics (Inst); Puma Biotechnology (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)
 
Ingo K. Mellinghoff
Honoraria - Roche
Consulting or Advisory Role - Agios; Black Diamond Therapeutics; Debiopharm Group; Puma Biotechnology; Voyager Therapeutics
Research Funding - Amgen; General Electric; Lilly
Travel, Accommodations, Expenses - Agios; AstraZeneca; Puma Biotechnology; Roche; Voyager Therapeutics
 
Meredith Becker Buxton
Research Funding - Amgen; Bayer; Eisai; Kazia Therapeutics; Kintara Therapeutics
 
Webster K. Cavenee
No Relationships to Disclose
 
Howard Colman
Consulting or Advisory Role - Abbvie; Adastra Pharmaceuticals; Bayer; Best Doctors, Inc; FORMA Therapeutics; Karyopharm Therapeutics; Newlink Genetics; Orbus Therapeutics; Private Health
Research Funding - Abbvie (Inst); Array BioPharma (Inst); Bayer; BeiGene (Inst); Bristol-Myers Squibb; DNAtrix (Inst); FORMA Therapeutics (Inst); Global Coalition for Adaptive Research (Inst); Kadmon (Inst); Merck (Inst); Newlink Genetics (Inst); Nuvation Bio; Orbus Therapeutics (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; FORMA Therapeutics; Karyopharm Therapeutics; Orbus Therapeutics
 
John Frederick De Groot
Employment - ZIOPHARM Oncology (I)
Leadership - ZIOPHARM Oncology (I)
Stock and Other Ownership Interests - Gilead Sciences; WuXi Biologics; ZIOPHARM Oncology (I)
Consulting or Advisory Role - Abbvie; Agios; Bioasis Technologies; Cure Brain Cancer Foundation; Debiopharm Group; DelMar Pharmaceuticals; Genentech/Roche; GenomiCare; GlaxoSmithKline; InSightec; Janssen; Karyopharm Therapeutics; KIYATEC; Magnolia Innovation; Merck; Mundipharma Research; Novartis; Prelude Therapeutics; resTORbio; Samus Therapeutics; Sapience Therapeutics; Tocagen; Voyager Therapeutics
Research Funding - CarThera (Inst); Haihe Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Other Relationship - VBI Vaccines
 
Benjamin M. Ellingson
Consulting or Advisory Role - Agios; Boston Biomedical; Global Coalition for Adaptive Research; Imaging Endpoints; Kazia Therapeutics; Medicenna; MedQIA; Neosoma; Northwest Biotherapeutics; Oncoceutics; Siemens; VBL Therapeutics
Research Funding - Janssen; Siemens
Travel, Accommodations, Expenses - Siemens
 
Gary B. Gordon
Employment - Ayala Pharmaceuticals
Leadership - Ayala Pharmaceuticals
Stock and Other Ownership Interests - Abbott; Abbvie; Ayala Pharmaceuticals; Molecular Templates; Others
Consulting or Advisory Role - Molecular Templates
 
Mustafa Khasraw
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Janssen; Lilly; Roche
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Specialised Therapeutics (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Andrew B. Lassman
Honoraria - Abbott Molecular
Consulting or Advisory Role - Bayer; BioClinica; Elsevier; FORMA Therapeutics; Karyopharm Therapeutics; Novocure; Orbus Therapeutics; QED Therapeutics; Sapience Therapeutics
Research Funding - Abbvie (Inst); Aeterna Zentaris (Inst); Agios (Inst); Bayer (Inst); BeiGene (Inst); BMS (Inst); Celldex (Inst); Genentech/Roche (Inst); Kadmon (Inst); Karyopharm Therapeutics (Inst); Millennium (Inst); Novartis (Inst); Oncoceutics (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst); RTOG Foundation (Inst); VBI Vaccines (Inst)
Patents, Royalties, Other Intellectual Property - Elsevier
Travel, Accommodations, Expenses - Abbott Molecular; AbbVie; Bayer; BioClinica; FORMA Therapeutics; Karyopharm Therapeutics; Novartis; Orbus Therapeutics; Pfizer; QED Therapeutics
 
Michael Lim
Stock and Other Ownership Interests - Egret Bioscience
Honoraria - Accuray; Agenus; Bristol-Myers Squibb; Merck; Oncorus; Stryker; tocagen
Consulting or Advisory Role - Accuray; Baxter; Bristol-Myers Squibb; InCephalo Therapeutics/University of Zurich; Insightec; Merck; PepVax; Pyramid Biosciences; Stryker; VBI Vaccines
Research Funding - Accuray (Inst); Agenus (Inst); Arbor Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); CellDex (Inst); ImmunoCellular Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Methods Patent for Combining Immunotherapy with Radiation (Inst)
Travel, Accommodations, Expenses - Accuray; Baxter; Bristol-Myers Squibb; Merck; Stryker
 
James R. Perry
No Relationships to Disclose
 
Kirk Tanner
Stock and Other Ownership Interests - Lilly; Moderna Therapeutics; Others; Vertex
Consulting or Advisory Role - Oncoheroes Biosciences
 
Michael Weller
Honoraria - Adastra Pharmaceuticals; Merck Serono; MSD; Nerviano Medical Sciences; Philogen
Consulting or Advisory Role - Bristol-Myers Squibb; Karyopharm Therapeutics; Medac; Orbus Therapeutics; Tocagen; Ymabs Therapeutics Inc
Research Funding - Apogenix (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novocure (Inst); Quercegen Pharmaceuticals (Inst)
 
W. K. Alfred Alfred Yung
Stock and Other Ownership Interests - De Novo Pharmaceuticals; DNATrix; Quadriga
Honoraria - Roche
Consulting or Advisory Role - Denovo Biopharma; DNAtrix; ILCT; Quadriga; Roche
Patents, Royalties, Other Intellectual Property - DNATrix
 
Timothy Francis Cloughesy
Stock and Other Ownership Interests - Chimerix; Katmai Pharmaceuticals; Notable Labs
Consulting or Advisory Role - Abbvie; Agios; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; DelMar Pharmaceuticals; DNAtrix; Global Coalition for Adaptive Research; GW Pharmaceuticals; Inovio Pharmaceuticals; Karyopharm Therapeutics; Katmai Pharmaceuticals; KIYATEC; Merck; Novartis; Pascal Biosciences; Pfizer; QED Therapeutics; Roche/Genentech; Sapience Therapeutics; Tocagen; VBI Vaccines; VBL Therapeutics
Patents, Royalties, Other Intellectual Property - U.S. Provisional Application No.: 62/819,322 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Filing Date: March 15, 2019 Inventor(s): David A. Nathanson et al. FH Reference No.: UCH-17760 (32246-17760) Your Reference No.: [UCLA 2019-630-1] US
Other Relationship - Global Coalition for Adaptive Research